Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva's Copaxone Continues To Widen MS Market Lead In U.S.

Executive Summary

The multiple sclerosis market underwent a shake-out in 2008 when Teva's Copaxone managed to pull ahead of more established beta interferon therapies, including Biogen Idec's Avonex; the drug now holds 38 percent of the nearly $4.5 billion U.S. market
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS051393

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel